The ATR-X syndrome is an X-linked disorder comprising severe psychomotor retardation, characteristic facial features, genital abnormalities, and a-thalassemia. We have shown that ATR-X results from diverse mutations of XH2, a member of a subgroup of the hellcase superfamily that includes proteins involved in a wide range of cellular functions, including DNA recombination and repair (RAD16, RAD54, and ERCC6) and regulation of transcription (SWl2/SNF2, MOT1, and brahma). The complex ATR-X phenotype suggests that XH2, when mutated, down-regulates expression of several genes, including the a-globin genes, indicating that it could be a global transcriptional regulator. In addition to its role in the ATR-X syndrome, XH2 may be a good candidate for other forms of X-linked mental retardation mapping to Xq13.
Introduction
X-linked mental retardation (XLMR) occurs at a frequency of between 1.8 and 3.4 per 1000 individuals and includes at least 50 distinct syndromes (Neri et al., 1994) . Together these represent the most frequent causes of mental retardation in males, and some forms of XLMR provide a significant contribution to mental handicap in manifesting female carriers. The ATR-X syndrome is a severe, nonprogressive type of XLMR characterized by its association with an unusual form of ~z-thalassemia that can be readily detected by demonstrating hemoglobin H (134) inclusions in the peripheral red blood cells (Weatherall et al., 1981 , cases 2 and 3; Wilkie et al., 1990; Gibbons et al., 1995) . Affected boys have a typical facial appearance, genital abnormalities, severe psychomotor retardation, and a wide range of minor congenital abnormalities. Carrier females may have very mild hematologic changes but are otherwise normal. Previous studies localized the ATR-X syndrome to an interval of approximately 11 cM between DXSI06 and DXYSIX (Xq12-q21.31) with a peak Iod score of 5.42 (DXS72) (Gibbons et al., 1992) ; a significant proportion of all XLMR maps to this region (Neri et al., 1994) .
We have previously suggested that the remarkably consistent core of clinical findings in boys with the ATR-X syndrome indicates that the molecular defect probably involves a single gene rather than a group of contiguous genes . The wide spectrum of tissues and systems affected, however, suggests that the mutations within such a gene exert pleiotropic effects throughout development. In this respect, it is of interest that female carriers have a remarkably skewed (greater than 20:1) pattern of X inactivation in tissues representing mesoderm (blood), endoderm (buccal mucosa), and ectoderm (hair root), consistent with a strong selective disadvantage conferred by the mutated gene (Gibbons et al., 1992) .
The invariable occurrence of a-thalassemia in this syndrome suggests that the X-linked gene encodes a protein that, when mutated, down-regulates expression of the structurally normal ~-globin genes (on chromosome 16) in addition to modifying expression of other (as yet unidentified) genes. Expression of the ~-globin genes has been extensively studied: the critical cis-acting regulatory sequences have been defined, and some of the proteins that interact with them have been identified Jarman et al., 1991) . In the ATR-X syndrome, we have previously shown that although all of these cis-acting regulatory sequences are intact and retain their normal patterns of methylation, the levels of a-globin mRNA and ~-globin chain synthesis are reduced to 30%-65% of normal (Wilkie et al., 1990 ). Analysis of a-globin gene expression in this syndrome may thus provide an opportunity to elucidate the mechanism(s) by which mutation of a transacting factor could perturb the function of target genes with widely differing roles.
To refine the localization of the disease gene responsible for the ATR-X syndrome, we have performed linkage analysis in nine further families and identified key recombinants that reduce the area of interest to 1.4 cM (estimated to be 15 Mb) between DXS453 and DXS72, within Xq13.1-q21.1. Recently, several cDNAs from this area have been isolated, and therefore we have examined these genes as candidates for the ATR-X syndrome. We have further characterized one of these cDNAs, which encodes a gene of the SNF2 family of putative helicases, and identified two premature in-phase stop mutations, seven missense mutations, and a small deletion that severely downregulates (to <1%) expression of this gene in ATR-X patients.
Results

Refining the Localization of ATR-X by Linkage Analysis
Previous linkage analysis (Gibbons et al., 1992) in seven pedigrees localized the ATR-X locus to the proximal region of Xq (Xq12-q21.31). In this study we examined a further nine families (ATR-X pedigree numbers 12, 14, 17, 20, 21, 22, 23, 24, and 25) . These and all other pedigrees used in this study are summarized in Gibbons et al. (1995) . Using data from all 16 families, two-point Iod scores were calculated for 0s between the ATR-X locus and five previously ordered polymorphic loci ( Figure 1 ; Table 1 ). A peak Iod score of 9.56 at 0 = 0 was seen at PGK1. DXS453 and DXS72 are the closest flanking markers that demonstrate recombination with the ATR-X locus. These loci lie approximately 1.4 cM apart (Wang et al., 1994) within the region Xq13.1-q21.1 and thus refine the localization of ATR-X to this segment of the X chromosome ( Figure 1) .
A Search for Mutations of ATR-X
High resolution cytogenetic analysis of all ATR-X patients studied to date has revealed no abnormality . Since this area of the genome has been well characterized (Schlessinger et al., 1993) , we examined the X chromosome of up to 26 affected boys from unrelated families by the use of polymerase chain reaction (PCR), pulsed field gel electrophoresis, or conventional Southern blot hybridization using 29 previously described markers distributed across this region (data not shown). Using this approach we found no evidence for allele loss or genomic rearrangement. In a further attempt to identify mutations, we used previously described cDNAs (DXSlOO5E and DXS1103E) and six partial cDNA fragments (clones 23.1, J15, J14, Eg, E4, and E13 ) that had been isolated by direct cDNA selection (Gecz et al., 1993; L. V. et al., unpublished data) using total yeast artificial chromosome (YAC) DNA from within the candidate region. Using the 84 bp cDNA fragment (E4) isolated with YAC4551 (which includes the marker DXS56; Figure 1 ), we noted an absent hybridization signal in one individual (26.3; proband in McPherson et al., 1995) out of 26 ATR-X patients ( Figure 2a ). This same band was also shown to be missing from 26.3 (data not shown) when the panel of DNA samples was rescreened with the probe XNP3/4 (1000 bp) obtained by reverse transcriptase (RT)-PCR of cDNA corresponding to the 3' end of a previously described gene that had been localized to this region Stayton et al., 1994) .
Characterization of cDNAs Corresponding to E4 and XNP3/4
Since both E4 and part of XNP3/4 were shown to be missing in patient 26.3, it seemed possible that they originated from the same gene. Northern blot analysis using RNA from Epstein-Barr virus (EBV)-transformed lymphoblasts from normal individuals showed that both probes identified indistinguishable, widely expressed 9.5 kb mRNA transcripts (data not shown), and subsequent sequence analysis (see below) confirmed that E4 lies entirely within XNP3/4. To allow further characterization of this gene in ATR-X patients, we used XNP3/4 and E4 to isolate a set of overlapping cDNA clones from human fetal brain and human heart cDNA libraries (Figure 3b ). We also generated and cloned cDNA fragments by RT-PCR of cDNA derived from a normal EBV-transformed lymphoblastoid cell line, using the previously described primers XNP3, XNP4, XNP7, and XNP8 or their reverse complements . These clones, which mapped back to YAC4551 (data not shown), were then sequenced. Subsequent analysis demonstrated that the clones we had characterized correspond to the previously described protein and cDNA sequences encoding a widely expressed putative helicase known as XNP or XH2 , as set out in Figure 3 . PGK1 and the dinucleotide tandem repeat sequences PY5-10 and PY2-31 lie on the same 450 kb YAC (Graeber et al., 1992) and were consequently treated as a single locus for the purpose of this analysis. Linkage analysis was performed using the LINKAGE program, version 5. Penetrance figures used for linkage analysis are given in Gibbons et al. (1992) . In addition to the clones corresponding to previously published sequences (GenBank accession numbers L34363 for XNP and U09820 for XH2), we also isolated and sequenced cDNAs that extend a further 1.5 kb in the 3' direction. The cDNA fragment 5.1 (Figure 3 ) contains a putative polyadenylation signal and a poly(A) tail, 14 nt downstream, confirmed by sequence comparison with genomic DNA. From Northern blot analysis (see below), we estimate that the XH2 mRNA transcripts are approximately 9.5 kb in length; our sequence data (covering 6.5 kb), combined with the previously published sequence of XH2 , cover 7605 bp of contiguous sequence, suggesting that there is an additional segment (2 kb) of uncloned sequence at the 5' end of the cDNA. We have not ruled out the possibility of an alternative polyadenylation signal further downstream of the signal that we have identified. It is interesting to note that have placed the initiation codon at position 53 of the current nucleotide sequence; however, this is somewhat arbitrary since the open reading frame is maintained upstream of this.
ATR-X Associated with a Partial Deletion of XH2
Preliminary studies with E4 and XNP3/4 suggested that at least part of the XH2 gene had been deleted in patient 26.3 (see above). Using the small cDNA probe E4, we detected no signal in genomic DNA. With the larger XNP3/4 cDNA fragment, which includes E4 (see Figure  3b ), both normal-sized and missing genomic fragments, corresponding to the missing E4 fragments, were noted.
To characterize the deletion further, we isolated a cosmid (ICRFc104A1814) from a flow-sorted X chromosome library (the Imperial Cancer Research Fund [ICRF] Reference Library) using XNP3/4. A 2.5 kb BamHI fragment from this cosmid, containing the E4 sequence (see Figure  2c ), identified breakpoint fragments in several different digests of genomic DNA from patient 26.3 (e.g., see Figure  2b ). Comparison of the restriction map of normal individuals and 26.3 was consistent with a genomic deletion of approximately 2 kb from within the 2.5 kb Bam HI fragment, suggesting that the 2.5 kb fragment spans the deletion. This fragment was therefore sequenced, and PCR primers located close to each BamHI site were designed. When DNA from a normal individual was amplified with these primers, a 2.5 kb band was identified, whereas when we used DNA from 26.3, a 0.5 kb band was seen. Comparison of the DNA sequence from the 0.5 kb DNA fragment with the normal sequence confirmed that there is a 1973 bp genomic deletion from this region (data available on request).
To evaluate the effect of this deletion on expression of the XH2 gene, we analyzed RNA derived from EBVtransformed lymphoblasts. Using primer XNP3/4, we observed two closely migrating transcripts of approximately 9.5 kb in RNA from normal individuals. In the proband 26.3 and in a similarly affected maternal cousin (26.7), both 9.5 kb transcripts were missing (see Figure 2d ), indicating that XH2 is down-regulated by this deletion and also showing that both transcripts originate from the same locus. On prolonged exposure, very faint faster-migrating bands were observed. To ensure that XH2 was the only gene disrupted by this deletion, a Northern blot was probed with a 4.6 kb Pstl genomic fragment spanning the deletion (see Figure 2c ). Apart from the 9.5 kb doublet previously observed with XNP3/4, no other transcripts were seen (data not shown).
These findings therefore provide strong evidence that the genomic deletion observed in 26.3 causes disruption and down-regulation of XH2, a candidate gene for the ATR-X syndrome. A Search for Other Mutations of XH2 in the ATR-X Syndrome We did not detect absent or altered bands on Southern blot analysis in any of the 25 other ATR-X patients studied, However, in view of the findings in 26,3, described above, it seemed likely that point mutations or small deletions might be presen t in these cases, causing alteration in XH2 structure or expression. To evaluate expression, RNA from EBV-transformed lymphoblasts derived from 24 ATR-X patients was examined by Northern blot analysis using XNP3/4. RNA was detected in all patients studied; however, in some there was a marked alteration in the relative intensities of the two XH2 transcripts, and the ratio was identically altered in other affected members of the same family (e.g., see Figure 2e ). These findings suggested that mutations in these families were causing some perturbation in XH2 mRNA expression or stability.
We next analyzed by single strand conformation polymorphism (SSCP) analysis the structure of XH2 cDNA de- rived from EBV-transformed lymphoblasts from 24 ATR-X patients, using primers designed to generate overlapping 150-300 bp fragments ( Figure 3d ; Table 2 ). In this way, 4.5 kb of the 9.5 kb mRNA transcript, including most of the currently known coding sequence, was analyzed. In addition, amplified fragments generated from primers 7 and 8, which contain an imperfect trinucleotide repeat , were examined and found to be of normal size in 24 patients. By SSCP analysis we detected 11 altered bands corresponding to cDNA fragments from nine unrelated pedigrees. In two cases, SSCP changes were present in adjacent fragments where a mutation occurred in the region of overlap between PCR fragments (Table 3) . Variant SSCP fragments were amplified and sequenced, revealing nine different mutations (Figure 4 ; Table 3 ); in one case, the same mutation was seen in two similarly affected individuals from the same family (21.1 and 21.2). In pedigrees 13 and 14, fetuses with the "affected" haplotype were found to have the same mutation as the affected proband. The locations of these mutations in XH2 are shown in Figure 3a . Two (C4635T and G4641T) give rise to premature in-phase stop codons. The remainder are missense mutations that fall in the central portion of the molecule, a region that is known to be highly conserved among members of the superfamily of DNA helicases to which XH2 belongs (Bork and Koonin, 1993) . Although the mutations did not fall precisely into the previously proposed motifs (I-VI), based on protein sequence alignment, with one exception (N1002S), they occurred in areas that are well conserved among members of the helicase superfamily ( Figure 5 ). It is interesting that none of the mutations involves a highly convserved amino acid, which may mean that such mutations are lethal. Given the relatively conservative amino acid change in N 1002S and its nonconserved location, we cannot be certain that this is the diseasecausing mutation in family 20. However, the nature of the other eight mutations identified here, their occurrence in similarly affected individuals from the same family, and their locations in highly conserved regions of XH2 suggest that they cause significant disruption of its structure and function, thereby leading to the ATR-X phenotype.
Discussion
We have shown that the ATR-X syndrome results from mutations involving XH2, a gene that lies in the region Xq13.3. A wid e variety of mutations distributed throughout the central portion of the XH2 protein give rise to a surprisingly uniform phenotype that includes severe psychomotor retardation, a similar pattern of facial dysmorphism, and a-thalassemia. Consistent with the complex ATR-X phenotype, studies of XH2 and its murine homolog Mxnp Stayton et al., 1994; unpublished data) 
Figure 5. Location of Six ATR-X Mutations in Relation to Conserved Domains Sequence alignment of various members of the helicase superfamily (indicated on the left). The locations of six mutations identified in ATR-X patients (arrows) are shown in relation to conserved regions both within and outside the helicase domains (overlined). The N1002S missense mutation that occurs in a nonconserved region is not shown. The amino acids are divided into blocks of ten, with the residue number for each family member given on the right.
have shown it to be a widely expressed gene that might play an important role in development of the central nervous system. At present, the role of XH2 in development of the urogenital system is not known but, since 96% of ATR-X patients also have genital abnormalities , it seems likely that XH2 will also be involved in this pathway. The most extreme urogenital abnormalities, causing severe hypogenitalism, male pseudohermaphroditism, and in some cases female gender assignment, were caused by a partial deletion of XH2, premature inphase stop codons (R1528" and E1530 *), and a missense mutation (C755R). We have previously shown that severe genital abnormalities appear to "breed true" with the disease (McPherson et al., 1995; Reardon et al., 1995) . It will therefore be interesting to see whether specific types of mutation, perhaps those producing no XH2 protein, are associated with this particular phenotype. Previous studies have shown that XH2 is subject to X inactivation and is exclusively transcribed from the active X chromosome . Female carriers of ATR-X have a markedly skewed pattern of X inactivation in all tissues that have been studied, and we previously considered whether this might be due to selection against the affected chromosome or to the direct involvement of the X inactivation center, which lies close to the ATR-X locus (X/ST in Figure 1 ). In the absence of any large chromosomal rearrangements involving both the X inactivation center and XH2 loci, selection seems the most likely explanation. If selection accounts for the skewed pattern of X inactivation seen in female carriers, this suggests that unless mutations in XH2 are independently selected against in each tissue, XH2 must be expressed prior to differentiation of the embryonic endoderm, ectoderm, and mesoderm in humans. It is therefore of interest that Mxnp is already expressed in the primitive streak at the earliest stage of mouse development (7.0 days postcoitum) that has yet been studied .
Sequence analysis has shown that XH2 belongs to the SNF2 subgroup (Kolst~ et al., 1993 ) of a superfamily of proteins with similar DNA-dependent ATPase (I and II in Figure 3a ) and proven or putative DNA helicase (III-VI in Figure 3a) domains (Bork and Koonin, 1993) . Regions outside the helicase domains also show considerable conservation among members of this SNF2 subgroup (Matson et al., 1994) . These proteins are involved in a wide variety of cellular functions, including mitotic chromosome segregation (lodestar), DNA recombination and repair (RAD16, RAD64, and ERCC6), and global regulation of transcription (SWl2/SNF2, MOT1, brahma) (reviewed by Carlson and Laurent, 1994) . Using comparative analysis, we found no additional protein motifs associated with particular subgroups of the SNF2 family (e.g., bromodomains [Haynes et al., 1992] , chromodomains [Delmas et al., 1993] , DNAbinding or activation motifs , kinases [Tsuchiya et al., 1992] , and TPR boxes [Davis et al., 1992] ). Furthermore, recent evidence has shown that although some proteins in this superfamily are predominantly involved with either repair (e.g., RAD16) or transcriptional control (e.g., SWl2/SNF2), the two processes are closely connected (Drapkin et al., 1994) . Therefore, at present, the best guide to the normal function of XH2 comes from an evaluation of the phenotypic effects of mutation. In contrast with other human genetic diseases (xerodema pigmentosum [Hoeijmakers, 1993] , trichothiodystrophy [Broughton et al., 1994] , and Cockayne's syndrome [Troelstra et al., 1992] ) that result from mutations in genes of the helicase superfamily, in the ATR-X syndrome there is no clinical evidence for ultraviolet sensitivity or the premature development of malignancy. Furthermore, cytogenetic analysis has not demonstrated any evidence of abnormal chromosome breakage or segregation. However, the consistent association of ATR-X, due to a wide range of independent mutations, with down-regulation of a-gtobin expression suggests that XH2 is involved in the regulation of gene expression.
Mutations of XH2 might affect any stage of gene expression, but the SNF2 family to which it belongs is distinct from the group of DEAD box RNA helicases, some members of which have been implicated in RNA processing, stability, or translation (Pain, 1986; Strauss and Guthrie, 1991 ; lost and Dreyfus, 1994) . From a functional point of view, perturbation of XH2 appears to resemble most closely the effects that would be expected from disruption of a global transcriptional regulator, the best-studied examples being brahma in Drosophila (Tamkun et al., 1992) and the SNF/ SWl family in Saccharomyces cerevisiae (Winston and Carlson, 1992) . Although the precise mechanism by which these proteins exert their effect is not known, they appear to regulate transcription of restricted classes of genes via interactions with gene-specific activators, most likely by altering chromatin structure to relieve repression (Carlson and Laurent, 1994) . In this respect, it is most interesting that mutations in XH2 down-regulate expression of the (~-globin genes but do not appear to affect the closely related I~-globin genes. Activation of the (~-and I~-globin genes appears to involve a common group of lineagespecific (GATA-1 and NF-E2) and ubiquitous (CACC box) DNA-binding proteins. However, despite their common ancestry, human a-and I~-globin clusters have been previously shown to lie in remarkably different chromosomal environments (reviewed by Vyas et al., 1992) . The a genes are associated with CpG-rich islands located in a constitutively "open," transcriptionally active chromatin domain that is early replicating in all cell types, and their expression is regulated by a remote tissue-specific enhancer. By contrast, the 13 cluster is contained within a segment of chromatin that opens and becomes early replicating in a tissue-specific manner under the influence of a remote locus control region (Grosveld et al., 1987; Forrester et al., 1990 ). In addition, unlike the ~ cluster, the 13 cluster contains several matrix attachment regions (Jarman and Higgs, 1988 ) that may act as histone H1 nucleation sites (Zhao et al., 1993) and thereby influence long-range chromatin structure. The specific effect of XH2 mutations on (z-rather than 13-globin expression may therefore indicate that XH2 is a transcriptional activator that, like other similar proteins (e.g., SNF/SWl and brahma), works via an interaction with chromatin. It is interesting to note that all the diverse mutations of XH2, including a deletion that severely reduces the level of XH2 mRNA, cause (z-thalassemia, implying that rather th an the (z genes being affected as "innocent bystanders" in these mutations, XH2 is normally necessary for their correct regulation. Further analysis of the role of XH2 in the control of gene expression is therefore likely to elucidate the normal mechanisms of (~-globin regulation.
It is of interest that many forms of XLMR and complex human genetic disorders map to Xq13-q21 (Schlessinger et al., 1993) . Although the patients that we have studied have been highly selected for a specific phenotype, they have mutations distributed throughout the XH2 gene. Although this might suggest that any perturbation of XH2 expression will cause ATR-X, mutations should be sought in other forms of XLMR that map to this region. We have identified several pedigrees in which affected individuals have a phenotype very similar to ATR-X but in whom we cannot detect hemoglobin H inclusions; these include a pedigree with the Juburg-Marsidi syndrome (SaugierVeber et al., 1995) . Analysis of XH2 in all of these families is currently underway.
Experimental Procedures
DNA/RNA Sources and Analysis
EBV-transformed lymphoblastoid patient cell lines were used as a source of both genomic DNA and RNA. cDNA was prepared from cell line RNA by RT-PCR as described by Brown et al. (1990) . YAC4551 (provided by Dr. A. Monaco, ICRF, Oxford, England) was used for mapping back cDNA probes. Cosmids covering the 3' end of the XH2 gene were obtained by screening the X chromosome flow-sorted ICRF Reference Cosmid Library (Lehrach et al., 1990) with probe XNP3/4. The 2.5 kb BamHI and the 4.6 kb Pstl fragments from cosmid ICRFc104A1814 were subcloned into pBluescript I1. Northern and Southern blots were performed as described in Sambrook et al. (1989) . Final washing conditions were performed at either room temperature or at 65°C in 0.1 x SSC and 0.1% SDS for 5 min.
cDNA Isolation and Characterization
Initially, a human fetal brain library in ~, phage (from Dr. P. C. Harris, Institute of Molecular Medicine, Oxford, England) was screened with E4. One cDNA was isolated that contained two EcoRI fragments (1.88 and 0.56) that were cloned into pBluescript II for further analysis. Three additional cDNAs (P12, P16, and data not shown) were isolated from this library after screening with the 0.56 fragment. Five additional cDNA fragments (hh4, 5.1, 5.2, 6 .2, and data not shown) were isolated from a human heart Z phage cDNA library (Stratagene Cloning Systems) or from a human fetal brain plasmid cDNA library (from Dr. D. J. Blake, Institute of Molecular Medicine, Oxford, England) prepared in the vector pcDNAII (Invitrogen Corporation), probing with either XNP3R/SR, the BamHI 2.5 kb genomic fragment, or the 2.1 kb BamHIPstl genomic fragment (Figure 2c ). cDNA fragments XNP3/4 and XNP3P,/8R were amplified from cDNA from a normal individual and cloned into pUC18 at the Smal site.
DNA Sequence Analysis
Double-stranded sequencing of genomic or cloned cDNA fragments (Chen and Seeburg, 1985) was performed with Sequenase T7 polymerase (United States Biochemicals) using sequential truncations (Henikoff, 1984) or selected oligonucleotide primers (see Table 2 ). ATR-X patients showing an altered SSCP band and normal control samples were directly sequenced after PCR amplification as described in Thein and Hinton (1991) .
PCR Amplification and SSCP Analysis
XNP3/4 and XNP7/8 were amplified from cDNA derived from a normal EBV-transformed lymphoblastoid line utilizing primers XNP3, XNP4, XNP7, and XNP8 using previously described conditions . Similarly, XNP3FESR was amplified using primers XNP3R and XNP8R, the reverse complements of XNP3 and XNPS, respectively. To characterize the 26.3 breakpoint, we employed primers Bam2.5f (5'-GATCCACCAAACCTCACAAATTCTG-3') and Bam2.5r (5"GCCA-GCCI-I-CTGCCTTATACI-rG-3'). Cycles were as follows: once at 94°C for 5 rain, at 52.7°C for 1 min, and at 72°C for 2.5 min; 28 times at 94°C for 1 rain, at 52.7°C for 1 min, and at 72°C for 2.5 rain; once at 94°C for 1 rain, at 52.7°C for 1 min, and at 72°C for 10 rain. Typically, all PCRs were performed in PCR buffer (50 mM KCI,10 mM Tris-HCI [pH 8.8]. 0.01% gelatin) containing 0.5-2.0 mM MgCI2, 200 p.M dNTPs, 0.5 I~M of each primer, 2.5 U/100 I11AmpliTaq (Perkin-Elmer Cetus), 100 ng of genomic DNA or 1 p.I of cDNA prepared as described above, in a final volume of 50 p.I. For SSCP analysis, PCRs were performed in 10 p,I with 1 I~1 of a 5-fold dilution of cDNA template and the addition of 0.1 Id of [(x-32P]dCTP (3000 Ci/mmol; Amersham). Annealing temperature was adjusted for each primer pair (Table 2) . Cycles were as follows: once at 94°C for 5 min, annealing for 1 min, and then at 72°C for 1 min; 28 times at 94°C 1 for min, annealing for 1 min, and then at 72°C for 1 rain; once at 94°C for 1 min, annealing for 1 min, and then at 72°C for 4 min. Analysis of labeled SSCP products was performed according to the method of Glavac and Dean (1993) .
